GlassScriptPhysician profile
Lisa Marie Knust
NPI 1336179134
$5,801.58
in general payments reported to CMS, 2019-2025
27 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,490 · 2020: $959 · 2021: $1,167 · 2022: $473 · 2023: $668 · 2024: $615 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $949.88 | 2019-2024 | Wegovy |
| Janssen Pharmaceuticals, INC | $746.62 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $714.85 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $531.35 | 2019-2023 | Fasenra |
| Abbvie INC. | $365.44 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $339.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.12 | 2019-2021 | |
| Glaxosmithkline, LLC. | $271.87 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Scpharmaceuticals INC. | $140.00 | 2024 | |
| Amgen INC. | $130.15 | 2019 | |
| Corium, LLC | $125.01 | 2023 | Azstarys |
| Pfizer INC. | $123.55 | 2019-2024 | |
| Axsome Therapeutics, INC. | $123.12 | 2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $121.26 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $111.37 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $109.52 | 2019 | |
| Boston Scientific Corporation | $108.14 | 2025 | General - Pain Management |
| Allergan, INC. | $85.78 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.44 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $68.29 | 2019-2025 | Capvaxive, Enflonsia, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $48.65 | 2020-2021 | |
| Amarin Pharma, INC. | $46.06 | 2020-2021 | |
| Exact Sciences Corporation | $43.15 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $34.59 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $29.85 | 2024 | Qelbree |
| Stryker Corporation | $27.25 | 2025 | Fixos, Smart Toe |
| Shire North American Group INC | $16.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Knust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.